Article ID | Journal | Published Year | Pages | File Type |
---|---|---|---|---|
2408347 | Vaccine | 2007 | 9 Pages |
Abstract
LTK63 and LTR72 both were very effective and safe mucosal adjuvants at all three dose levels employed in these studies. Both significantly enhanced the protection of a marginally effective dose of rRV against aerosol-delivered ricin challenge. LTK63 stimulated cytokines, which could be surrogate markers of efficacy, with human relevance potential. In spite of the better efficacy, rRV with LTK63, or with LTR72, failed to reduce the ricin-related lung injury. Most likely, a larger than suboptimal dose could resolve the lung injury of the vaccinated mice in the presence of a larger dose of the mucosal adjuvant.
Related Topics
Life Sciences
Immunology and Microbiology
Immunology
Authors
Meir Kende, Xiaolian Tan, Carly Wlazlowski, Rebecca Williams, Changhong Lindsey, Giuseppe Del Giudice,